The TPM3‐NTRK1 rearrangement is a recurring event in colorectal carcinoma and is associated with tumor sensitivity to TRKA kinase inhibitionElena Ardini, Antonella Isacchi, Marcello Gambacorta et al.|Molecular Oncology|2014Cited by 156
Afatinib Is a New Therapeutic Approach in Chordoma with a Unique Ability to Target EGFR and BrachyuryPaola Magnaghi, Antonella Isacchi, Barbara Salom et al.|Molecular Cancer Therapeutics|2017Cited by 93
Cell Line Identity Finding by Fingerprinting, an Optimized Resource for Short Tandem Repeat Profile AuthenticationAlessio Somaschini, Roberta Bosotti, Nadia Amboldi et al.|Genetic Testing and Molecular Biomarkers|2013Cited by 14
Optimization of Diarylthiazole B‐Raf Inhibitors: Identification of a Compound Endowed with High Oral Antitumor Activity, Mitigated hERG Inhibition, and Low Paradoxical EffectMaurizio Pulici, Marina Ciomei, Gabriella Traquandi et al.|ChemMedChem|2014Cited by 9
Abstract 5163: Characterization of NMS-E194, a selective and potent PERK inhibitor with efficacy in the KMS-11 multiple myelomaClaudia Perrera, Barbara Valsasina, Maurizio Pulici et al.|Cancer Research|2017Cited by 1